AZD1775 increased the dependency of DLBCL cells on BCL-2 and MCL-1, with enhanced apoptosis when AZD1775 was combined with BCL2(venetoclax/navitoclax) or MCL-1 (S63845) inhibitors (111). The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.